Astellas Pharma Inc., a pharmaceutical company conducting business in more than 70 countries across the globe, announced that it has entered into a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.
Initial projects of mutual interest will be focused in key areas of R&D investment for Astellas, including oncology, rare disease, and cell and gene therapy.
Through the alliance, Astellas and Mass General Brigham aim to: Accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers; Translate innovative research into clinical trials and actionable solutions that address serious unmet needs and aim to improve healthcare for all; Leverage scientific and clinical expertise to inform and accelerate the development of novel therapies.
Academic collaborations are a critical component of Astellas’ innovation strategy. They underpin the company’s ongoing commitment to enhance scientific knowledge, better understand diseases and modalities, optimize clinical trials, and ultimately, transform patient care. Located in Boston, Massachusetts, Mass General Brigham is one of the leading academic medical centres in the United States. The healthcare system has extensive discovery and translational research in all areas, including oncology, rare disease, and cell and gene therapy, through its research initiatives and thematic centres, including the Gene and Cell Therapy Institute. This collaboration will leverage Mass General Brigham’s clinical and research expertise, and capabilities including clinical data and human-derived cell models.
Chris Coburn, chief innovation officer, Mass General Brigham, said: “Industry alliances are critical to advancing novel therapies toward commercialization and bringing the ‘bench to the bedside’. This collaboration supports three critical areas of rapid clinical advancement and high patient need: oncology, rare diseases, and cell and gene therapy and reflects our commitment to advancing patient-centered research and innovation.”
Tadaaki Taniguchi, MD, PhD, chief medical officer, Astellas, said: “We are incredibly excited about this collaboration with Mass General Brigham – one of the leading biomedical research organizations in the US – and the promise it represents. As a global innovation community, we face significant challenges when exploring complex, potential breakthrough modalities. Only by working alongside the most innovative institutions and experts can we find solutions that can help deliver life-changing value to patients, faster.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!